+44 7474964491
[email protected]
Contact Us

Blogs

Stay informed with the latest trends, updates, and expert insights in quality assurance, regulatory affairs, and compliance. Our blogs are designed to keep you ahead in the ever-evolving world of healthcare and pharmaceuticals.

Subscribe Now
Your CMO Has a GMP Certificate. Here’s Why That’s Not Enough for Your Next MHRA Inspection 
16 Jul
Pharma Audits

Your CMO Has a GMP Certificate. Here’s Why That’s Not Enough for Your Next MHRA Inspection 

Generic Drug Companies and Signal Detection: Why You Can’t Copy Your Originator’s PV System
14 Jul
Risk-Based Audits

Generic Drug Companies and Signal Detection: Why You Can’t Copy Your Originator’s PV System

The Hidden Cost of Repeat Inspection Findings – and How to Break the Cycle 
09 Jul
Risk-Based Audits

The Hidden Cost of Repeat Inspection Findings – and How to Break the Cycle 

Five Indian Pharma Companies Got FDA Warning Letters in Q1 2026 for the Same Mistake: Here’s the Pattern 
07 Jul
Pharmacovigilance Services

Five Indian Pharma Companies Got FDA Warning Letters in Q1 2026 for the Same Mistake: Here’s the Pattern 

Import Alert 66-40 Explained: How One Data Integrity Finding Can Block Your Entire Supply Chain for 18 Months
02 Jul
Risk-Based Audits

Import Alert 66-40 Explained: How One Data Integrity Finding Can Block Your Entire Supply Chain for 18 Months

The FDA Just Issued Its First Warning Letter for AI Misuse in CGMP Documentation: Here’s What Happened
30 Jun
Risk-Based Audits

The FDA Just Issued Its First Warning Letter for AI Misuse in CGMP Documentation: Here’s What Happened

GDP Compliance for Cold Chain Logistics: Updated Requirements and Audit Checklist
25 Jun
GVP Audits

GDP Compliance for Cold Chain Logistics: Updated Requirements and Audit Checklist

The New EU Pharmaceutical Legislation 2026: What Changes for Pharmacovigilance?
23 Jun
Pharmacovigilance Services

The New EU Pharmaceutical Legislation 2026: What Changes for Pharmacovigilance?

FDA Draft Guidance on Responding to Form 483 Observations: A Practical Guide for CGMP Sites
18 Jun
Pharma Audits

FDA Draft Guidance on Responding to Form 483 Observations: A Practical Guide for CGMP Sites

FDA’s New Overseas Inspection Approach: What Pharma Sites Need to Know
16 Jun
Pharmacovigilance Services

FDA’s New Overseas Inspection Approach: What Pharma Sites Need to Know

EMA and FDA Issue Joint Principles on AI in Medicine Development: What It Means for PV Teams
11 Jun
Pharmacovigilance Services

EMA and FDA Issue Joint Principles on AI in Medicine Development: What It Means for PV Teams

GDP 2026: Understanding MHRA, DSCSA, and Global Traceability Requirements
09 Jun
Pharma Audits

GDP 2026: Understanding MHRA, DSCSA, and Global Traceability Requirements

Root Cause Analysis Tools for GxP CAPA: When to Use Ishikawa, 5-Why and Fault Tree Analysis 
04 Jun
GVP Audits Pharmacovigilance Services

Root Cause Analysis Tools for GxP CAPA: When to Use Ishikawa, 5-Why and Fault Tree Analysis 

PSMF Maintenance Checklist: What Needs Updating After a Licence Variation, Product Transfer or MAH Change
02 Jun
Pharma Audits

PSMF Maintenance Checklist: What Needs Updating After a Licence Variation, Product Transfer or MAH Change

CE Mark vs National Device Approvals: How Global Medical Device Manufacturers Should Plan Their Compliance Strategy in 2026
28 May
Pharmacovigilance Services

CE Mark vs National Device Approvals: How Global Medical Device Manufacturers Should Plan Their Compliance Strategy in 2026

EMA, FDA and MHRA GMP Annex Revisions 2026- 2028: What Every Pharma QA Team Must Prepare For
26 May
Pharma Audits

EMA, FDA and MHRA GMP Annex Revisions 2026- 2028: What Every Pharma QA Team Must Prepare For

GMP Mock Inspection for Pharmaceutical Manufacturers: What Global Regulators Check That Internal Teams Miss
21 May
Pharma Audits

GMP Mock Inspection for Pharmaceutical Manufacturers: What Global Regulators Check That Internal Teams Miss

How to Respond to a Regulatory Deficiency Letter: A Step-by-Step CAPA Guide for Pharmaceutical Sites
19 May
GVP Audits Pharma Audits

How to Respond to a Regulatory Deficiency Letter: A Step-by-Step CAPA Guide for Pharmaceutical Sites

EU QPPV Services: Cost Comparison In-House vs Outsourced QPPV for MAHs in 2026
14 May
Pharmacovigilance Services

EU QPPV Services: Cost Comparison In-House vs Outsourced QPPV for MAHs in 2026

End-to-End GxP Quality and Pharmacovigilance Services: Integrated vs Fragmented PV
12 May
Pharmacovigilance Services

End-to-End GxP Quality and Pharmacovigilance Services: Integrated vs Fragmented PV

Drug Safety Consulting for Social Media ADR Reporting: NLP and Data Mining Strategies
07 May
Pharmacovigilance Services

Drug Safety Consulting for Social Media ADR Reporting: NLP and Data Mining Strategies

GxP Quality Services: FDA’s 112 Warning Letters and System Misalignment Findings
05 May
Risk-Based Audits

GxP Quality Services: FDA’s 112 Warning Letters and System Misalignment Findings

Pharmacovigilance Audit Services: Verifying Social Media Listening Programs for Regulatory Compliance
30 Apr
Pharmacovigilance Services

Pharmacovigilance Audit Services: Verifying Social Media Listening Programs for Regulatory Compliance

DARWIN EU Real-World Evidence: How Drug Safety Consulting Services Use 250 Million Patient Records
28 Apr
Pharma Audits

DARWIN EU Real-World Evidence: How Drug Safety Consulting Services Use 250 Million Patient Records

Before Your QA Meeting: 10 Quality Signals Every Leader Should Track
23 Apr
Pharma Audits Risk-Based Audits

Before Your QA Meeting: 10 Quality Signals Every Leader Should Track

Evidence Collection Flaws That Trigger Escalated Observations in Hybrid Audits
21 Apr
GVP Audits Pharma Audits

Evidence Collection Flaws That Trigger Escalated Observations in Hybrid Audits

Visual Inspection 4.0: Machines That Never Miss a Defect (And Regulators Love It)
16 Apr
Pharma Audits

Visual Inspection 4.0: Machines That Never Miss a Defect (And Regulators Love It)

How to Survive a Hybrid GMP Inspection Without a Single Observation
14 Apr
Pharmacovigilance Services Risk-Based Audits

How to Survive a Hybrid GMP Inspection Without a Single Observation

RMP 2.0: Digital Risk Management Plans Every Clinical Team Should Be Using
09 Apr
Risk-Based Audits

RMP 2.0: Digital Risk Management Plans Every Clinical Team Should Be Using

Biosimilars Under the Microscope: Post-Marketing Safety Shifts You Can’t Ignore
07 Apr
Pharmacovigilance Services

Biosimilars Under the Microscope: Post-Marketing Safety Shifts You Can’t Ignore

E2B(R3) Deadline April 2026: Is Your ICSR Submission Process FDA-Ready?
02 Apr
Pharmacovigilance Services

E2B(R3) Deadline April 2026: Is Your ICSR Submission Process FDA-Ready?

Annex 15 Revision: Key Impacts on Qualification and Validation for GDP Operators
31 Mar
Pharma Audits

Annex 15 Revision: Key Impacts on Qualification and Validation for GDP Operators

Navigating Dual MHRA/EMA Pharmacovigilance Obligations Post-Windsor Framework
26 Mar
Pharmacovigilance Services

Navigating Dual MHRA/EMA Pharmacovigilance Obligations Post-Windsor Framework

EU GMP Annex 22 (Artificial Intelligence): What GMP-Regulated Manufacturers Must Do Before the Effective Date
24 Mar
Pharmacovigilance Services

EU GMP Annex 22 (Artificial Intelligence): What GMP-Regulated Manufacturers Must Do Before the Effective Date

EU Pharma Package 2026: What It Means for GMP/GDP Operators Now
19 Mar
Pharma Audits

EU Pharma Package 2026: What It Means for GMP/GDP Operators Now

EudraVigilance Data Masking in ICSRs: Breaking Down the New GVP Module VI Addendum II
17 Mar
Pharmacovigilance Services

EudraVigilance Data Masking in ICSRs: Breaking Down the New GVP Module VI Addendum II

AI-Powered Signal Detection in 2026: Regulation, Use & Inspector Expectations
12 Mar
Risk-Based Audits

AI-Powered Signal Detection in 2026: Regulation, Use & Inspector Expectations

Third‑Party PV Subcontractors in the Crosshairs: How to Audit‑Proof Your Vendor Agreements
10 Mar
Pharma Audits

Third‑Party PV Subcontractors in the Crosshairs: How to Audit‑Proof Your Vendor Agreements

GVP Module IX Update in Q2 2026: What’s Changing and How to Prepare Now
05 Mar
GVP Audits

GVP Module IX Update in Q2 2026: What’s Changing and How to Prepare Now

Signal Management Overhaul: How to Adapt Your SOPs After the Deletion of Article 21(2)
03 Mar
Pharmacovigilance Services

Signal Management Overhaul: How to Adapt Your SOPs After the Deletion of Article 21(2)

ESMP Compliance in 2026: EMA Pharmacovigilance & Shortage Reporting Essentials
26 Feb
Pharmacovigilance Services

ESMP Compliance in 2026: EMA Pharmacovigilance & Shortage Reporting Essentials

Unannounced FDA GMP Inspections: Readiness Guide for Foreign Facilities
24 Feb
GVP Audits

Unannounced FDA GMP Inspections: Readiness Guide for Foreign Facilities

ICH E6(R3) & CRO Oversight: Risk-Based Vendor Audit Strategies
19 Feb
Risk-Based Audits

ICH E6(R3) & CRO Oversight: Risk-Based Vendor Audit Strategies

EU Pharmacovigilance Regulation 2025/1466: GvP Vendor Audit Essentials Before Feb 2026
17 Feb
Pharmacovigilance Services

EU Pharmacovigilance Regulation 2025/1466: GvP Vendor Audit Essentials Before Feb 2026

Why 87% of FDA Warning Letters Require External GMP Consultants
12 Feb
Pharma Audits

Why 87% of FDA Warning Letters Require External GMP Consultants

GDP Compliance Support for Pharmaceutical Wholesalers Under Inspection
10 Feb
Risk-Based Audits

GDP Compliance Support for Pharmaceutical Wholesalers Under Inspection

CAPA Remediation Support After Regulatory Inspections
05 Feb
Pharmacovigilance Services

CAPA Remediation Support After Regulatory Inspections

Vendor Audit Programs for GMP and PV: What Regulators Expect to See
03 Feb
GVP Audits

Vendor Audit Programs for GMP and PV: What Regulators Expect to See

QPPV Services for MAHs: Defining Real Oversight in Outsourced PV Models
29 Jan
Pharma Audits Pharmacovigilance Services

QPPV Services for MAHs: Defining Real Oversight in Outsourced PV Models

Do You Need a Pharmacovigilance Audit? Key Signs for UK Pharma Companies
27 Jan
Pharma Audits

Do You Need a Pharmacovigilance Audit? Key Signs for UK Pharma Companies

Internal vs External Audits in GMP and Pharmacovigilance: What UK Regulators Expect
22 Jan
Pharma Audits

Internal vs External Audits in GMP and Pharmacovigilance: What UK Regulators Expect

Let’s build a GxP-compliant future together.

Have a project in mind?

Partner with us to elevate your quality systems, ensure compliance, and drive meaningful business transformation.

Contact Us Now

Built with passion and purpose. Helping you grow smarter, not harder.

QUICK LINKS

CONTACT US

+44 7474964491
[email protected]

Newsletter Signup

Subscribe to our newsletter for the latest insights

Copyright © 2026 Quality Vigilance Ltd | All Rights Reserved || Powered by Prabisha Consulting

Newsletter Signup

Subscribe to our newsletter for the latest insights